The GLP-1 category is the most policy-sensitive corner of cash-pay healthcare and the most crowded with claims nobody can substantiate. We build acquisition for providers who intend to be operating in it in three years.
Review Your GLP-1 Acquisition FunnelGLP-1 provider marketing is patient acquisition for licensed providers and provider-affiliated programmes offering GLP-1 receptor agonist therapy as part of supervised metabolic care. It covers demand generation, eligibility-first screening, consultation booking, and continuation support — under advertising policies and product-description rules stricter than almost any other healthcare category.
Two facts shape every asset we build. Medical providers independently determine eligibility, so no campaign can promise a prescription. And FDA-approved and compounded medications are not the same thing, so no copy may blur them.
For providers whose model is supervised care, not volume prescribing.
Clinics and provider groups where a licensed clinician assesses, prescribes where appropriate, and follows the patient over time.
Multi-state programmes needing state-aware funnels, defensible product language, and channels that will not be shut down mid-scale.
Med spas, hormone clinics, and primary-care-adjacent practices extending into metabolic care who need the category's policy constraints handled from day one.
Advertisers whose campaigns were disapproved or accounts limited, who need the underlying creative and page issues resolved before rebuilding.
Guaranteed-approval language, branded-medication comparisons, and dramatic transformation imagery are everywhere in this category. Some of it is unlawful, much of it is against platform policy, and all of it sets a price and expectation anchor that responsible providers have to work against.
Medication-adjacent creative, personal-attribute implications, and landing pages that read as pharmacy pages rather than provider pages all trigger review. Because the disapproval reason is generic, teams rebuild by guesswork and often reintroduce the same trigger.
Broad GLP-1 interest generates enormous enquiry volume, much of it from people who will not meet clinical criteria. Without screening up front, the provider ends up delivering rejections at the end of the funnel — expensive for the clinic and a poor experience for the patient.
Eligibility first, claims last. The order is deliberate.
We document exactly what the programme provides, what is FDA-approved and what is compounded, what the price includes, and what recurs. Every downstream asset is written from that document, and anything it does not support does not get written.
The funnel establishes state, programme criteria, and readiness before it asks for commitment, and tells people who are not a fit plainly. This protects clinical time and keeps the consultation calendar a real metric.
Creative built to avoid personal-attribute implications, outcome claims, and branded-product comparisons — positioned on supervision, assessment, and programme structure. Reviewed against policy before spend, not after a rejection.
Fast response, short time-to-appointment, reminder sequencing, and reschedule recovery — the same show-rate discipline we apply across telehealth, which in this category is where a large share of paid demand is lost.
Where the client can lawfully report it, we measure through to first fill and continuation, so channels are judged on patients who stay in the programme rather than on enquiry counts.
These statements appear in our client-facing standards and govern every asset we produce.
We decline these regardless of what competitors are running, and we say so at the proposal stage rather than after signing.
Beyond the regulatory exposure, guarantee-style messaging attracts the patients least likely to complete a programme: people expecting a prescription rather than supervised care. They convert at the top of the funnel, fail eligibility or churn in month one, and inflate refund volume.
Restrictive language is not a handicap in this category. It is a filter that improves the composition of the patients who arrive.
Measured on clinically appropriate patients who continue, not on enquiry volume.
Before any agreement we will review your live assets against category policy and product-language rules and show you, specifically, what we would change and why. That review is the demonstration.
We publish no client names or outcome figures for this category. Any figure shared in a proposal carries its vertical, date range, baseline, budget context, and result definition, with the caveat that performance varies.
No. Eligibility is determined independently by a licensed provider based on clinical assessment, and no marketing system has any influence over it. Any agency implying otherwise is describing an outcome it cannot control and creating exposure for the provider who runs the campaign.
Digital Wellness Partners is a marketing and growth operator. We are not a healthcare provider, pharmacy, law firm, or regulatory advisor. Medical providers independently determine eligibility for treatment; a marketing campaign does not guarantee a prescription. Compounded medications are not FDA-approved and are not equivalent to FDA-approved branded products. Clients should obtain qualified legal, privacy, medical, and regulatory advice for their specific offer.
Written by Simeon Krastev · Last reviewed August 7, 2026
We review your live creative, landing pages, and product language against category policy, then show you the funnel changes that improve accepted-patient cost.
Review Your GLP-1 Acquisition Funnel